Who owns pembrolizumab?

Who currently owns pembrolizumab (Keytruda) rights?

Pembrolizumab is marketed as Keytruda, which is owned by Merck (Merck & Co.) in the United States and other markets. Merck holds the commercial rights to Keytruda/pembrolizumab as the brand’s manufacturer and main marketer.

Does patent or “ownership” depend on the country?

Yes. Ownership can vary by geography because patents, regulatory approvals, and licensing deals are granted and enforced country by country. Different entities may hold certain patents or have local manufacturing/licensing roles even when Merck is the brand owner/marketer for Keytruda.

What about patents tied to pembrolizumab—who holds those?

Patent ownership can be split across Merck entities and other assignees for specific formulations, delivery methods, manufacturing processes, or related technologies. A useful place to check assignees by patent is DrugPatentWatch, which tracks relevant patents and legal events for pembrolizumab. [1]

Sources:
[1] https://www.drugpatentwatch.com/